

IQ-AI Limited

08:52 12 Jun 2019

IQ-AI surges as Imaging Biometrics signs business development deal with CorTechs Labs

IQ-AI Limited's (LON:IQAI) shares surged on Wednesday after its subsidiary, Imaging Biometrics (IB), signed a non-exclusive business development and sales deal with brain analysis firm CorTechs Labs.

The medical software and services group said the agreement would provide its products with "extended and immediate" sales representation in the US and other international markets, while CorTech would add IB's software and exclusive algorithms to its portfolio.

READ: IQ-AI's Imaging Biometrics featured in American Journal of Neuro Radiology

The product suite includes IB's StoneChecker software, which helps analyse kidney stones, as well as IB Neuro which provides tumour biology data and the IB Delta Suite which helps clinicians distinguish tumour progression from treatment effects.

IQ-AI said IB's products would complement those of CorTechs, which specialises in assessing neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.

David Smith, IB's chief executive, said the deal meant IQ-AI's products would have "direct sales representation worldwide" for the first time, and that the firm was "very excited" about the shared revenue potential of the agreement.

"CorTechs Labs has a well established and rapidly growing sales and marketing team who can introduce IB's portfolio to their existing and new clients", he added.

In mid-afternoon the shares were 8.3% higher at 1.3p.

--Adds share price--

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

Price: 4.701

Market Cap: £6.57 m

1 Year Share Price Graph



November 2018 May 2019 November 20

Share Information

Code: IQAI

Listing: LSE

52 week High Low
15.99 0.95

Sector: Retail

Website: www.imagingbiometrics.com

Company Synopsis:

IQ-AI Limited is an investment company. The Company focuses on opportunities in the technology and logistics sectors. The Company seeks primarily to focus on making investments in private businesses.

action@proactiveinvestors.com

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).